REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > In Vivo Diagnosis Or In Vivo Testing > Magnetic Imaging Agent (e.g., Nmr, Mri, Mrs, Etc.) > Transition, Actinide, Or Lanthanide Metal Containing Transition, Actinide, Or Lanthanide Metal ContainingTransition, Actinide, Or Lanthanide Metal Containing patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/15/07 - 20070059246 - Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability The use of contrast agents of molecular weight lower than 5000 Dalton and including at least one residue of a biliary acid for the preparation of diagnostic contrast compositions for the microvascular permeability assessment is disclosed. ... 09/21/06 - 20060210478 - Steady state perfusion methods Methods for assessing ischemic coronary artery disease are provided. The methods include administering a contrast agent that binds to a serum protein component to an animal and obtaining an MR image of the animal's myocardium during a period when the animal is experiencing hyperemia. ... 09/14/06 - 20060204445 - Cell scaffold matrices with image contrast agents The invention is directed to methods and compositions for monitoring remodeling of an artificial tissue construct using image or contrast enhancing agents. The invention allows the growth, development, and remodeling of the artificial tissue to be monitored. ... 08/31/06 - 20060193781 - Magnetic resonance imaging of metal concentrations Provided herein is a method of magnetic resonance imaging (MRI) for in vivo mapping of concentration of a target metal ion in at least one tissue using a contrast agent selectively sensitive for the amount of target metal ion where the contrast agent itself contains a non-hydrogen imaging nucleus. Also ... 08/03/06 - 20060171895 - Medical imaging reference devices A medical device can be placed within or on the body of a patient. The device can include one or more imaging agents to allow visualization of the location of the device by an imaging system such as an MRI, an ultrasound, a PET, a CT, or an IR imaging ... 07/06/06 - 20060147380 - Integrin targeted imaging agents Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for αvβ3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, ... 06/29/06 - 20060140871 - Magnetic resonance imaging of prostate cancer Paramagnetic or superparamagnetic nanoparticle-ligand conjugates that include a recognition ligand that interacts with a component on the surface of a prostate cancer cell. Nanoparticle-ligand conjugates of the invention may be used for magnetic resonance imaging of prostate cancer, or for treatment of tumors by targeted thermal ablation. ... 06/29/06 - 20060140870 - Method for assessing tumor response to cancer treatment A method for measuring tumor response to a cancer therapy is provided. The method comprises the steps of injecting a polymeric contrast agent in a subject; obtaining a series of magnetic resonance image signals of the contrast agent in the tumor for up to about 60 minutes; and determining a ... 06/01/06 - 20060115431 - Procedures of cellular labelling with paramagnetic complexes for mri applications The present invention relates to paramagnetic complexes based on lantanides or transition metals administered in the form of particulates internalysed by cells and whose presence in the cells can be detected by MRI techniques. ... 05/18/06 - 20060104908 - Polymerization method for the synthesis of polypeptide imaging agents A method for synthesizing extended poly(amino acids) conjugated to imaging agents, such as DTPA, is disclosed. The amino acid is initially conjugated to the imaging agent at the monomer stage, followed by formation of the corresponding N-carboxyanhydride. The method utilizes catalyzed ring opening polymerization of the N-carboxyanhydride of the amino ... 05/04/06 - 20060093555 - Imaging inflammatory conditions using superparamagnetic iron oxide agents The present invention is directed to the field of magnetic resonance imaging (MRI) using superparamagnetic iron oxide (SPIO) agents. In particular, the present invention is directed to cationic, nonagglomerated, nontoxic SPIO agents, methods for imaging conditions associated with inflammatory responses using the disclosed SPIO agents, and methods for managing inflammatory ... 04/27/06 - 20060088474 - Endohedral metallofullerene contrast agents An image contrast agent for creating an image of a portion of a body is disclosed. The contrast agent can provide contrast for two different types of imaging techniques, such as x-ray imaging and magnetic resonance imaging. The contrast agent includes an endohedral metallofullerene compound with an atom encapsulated in ... 01/12/06 - 20060008416 - High resolution metabolic brain imaging This invention provides a method for determining whether a subject is afflicted with Alzheimer's disease by comparing the metabolic activity of the subject's hippocampal entorhinal cortex with that of a second region of the subject's brain. This invention further provides a method for determining whether a subject is afflicted with ... 12/08/05 - 20050271593 - Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof The present invention relates to a process for preparing water-soluble and dispersed iron oxide (Fe3O4) nanoparticles and application thereof, characterized in which two-stage additions of protective agent and chemical co-precipitation are employed in the process. In the first stage, Fe3O4 nanoparticles are obtained using absorbent-reactant coexistence technology. In the second ... 11/03/05 - 20050244337 - Medical device with a marker A contrast-enhancing agent that has a saturation magnetization of at least 1.5 Tesla and that, when contacted with MRI radiation, provides a first gray scale response that is substantially uniform and that has a resolution of at least about 1 millimeter. When the contrast-enhancing agent is repeatedly contacted with said ... 06/09/05 - 20050123480 - Water-soluble paramagnetic substance for reducing the relaxation time of a coolant and corresponding method Use of a water-soluble paramagnetic substance to reduce the relaxation time of a coolant and corresponding method The invention relates to the use of a water-soluble paramagnetic substance, in particular a magnetic resonance contrast medium, to reduce the magnetic resonance relaxation time of a coolant for magnetic resonance systems. Furthermore ... ### FreshPatents.com Support |